Loading asset research
Pharvaris N.V. Ordinary Shares
PHVSNasdaq · USD · StocksQuote as of · Exchange session not verified$38.02
+1.36%
Today
PHVS
Loading 1D prices…
Market cap
$2.7B
Volume
1.4M
52w high
$43.2552w low
$20.65Company profile
Pharvaris N.V. Ordinary Shares
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Zug, United States
Employees
148
Fiscal year end
1231
CIK
1830487
Session & valuation
Open$38.12
Previous close$37.51
Day high$40.60
Day low$37.47
30-day avg. volume874.7K
Outstanding shares65.2M
Diluted EPS-$2.97
Latest annual period
P/E (trailing)-12.80
P/E (forward)-12.08
Price / book7.63
Beta-2.32
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares | $2.7B | $22.5M | -902.10% | -$1.72 | +4.30% | Buy |
| IRONDisc Medicine Inc. Common Stock | $2.7B | $0.00 | — | -$6.01 | -5.62% | Buy |
| ZLABZai Lab Limited American Depositary Shares | $2.7B | $457.2M | -38.39% | -$0.16 | -0.17% | Buy |
| ATAIAtaiBeckley Inc. Common Stock | $2.7B | $4.1M | -16142.02% | -$2.91 | 0.00% | Hold |
| NRIXNurix Therapeutics Inc. Common stock | $2.6B | $84M | -314.90% | -$3.05 | -2.71% | Buy |